In an interview with Stockhead‘s Sarah Hughan, LTR Pharma Executive Chairman Lee Rodne spoke of the Company’s successful $10.5 million capital raise, and how the funds would be allocated to fast-track commercialisation of its fast-acting nasal spray treatment for erectile dysfunction (ED), SPONTAN.

“We’re scaling up our commercial manufacturing, and getting prepared to launch here in the Australia market under the under the Australian Special Access Scheme, as well as getting a direct to consumer website built to launch SPONTAN in the Australian marketplace.”

Shortz: LTR Pharma (ASX:LTP) from Stockhead on Vimeo.